The burden of diabetes and hyperlipidemia in treated hiv infection and approaches for cardiometabolic care

Current HIV/AIDS Reports

Volumn 9, Issue 3, 2012, Pages 206-217

  Samaras, Katherine ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Cardiometabolic care; Diabetes; Fat; Heart; HIV; Hyperlipidemia; Insulin resistance; Lipid; Metabolic; Myocardial infarction

Indexed keywords

ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; INSULIN; LOPINAVIR; METFORMIN; NICOTINIC ACID; PRAVASTATIN; REPAGLINIDE; RITONAVIR; ROSUVASTATIN; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

AGE; ARTICLE; BODY FAT; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG EXPOSURE; FAMILY HISTORY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; METABOLIC SYNDROME X; MIXED INFECTION; OBESITY; PREVALENCE; SCREENING; SEX DIFFERENCE; SINGLE DRUG DOSE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; AUSTRALIA; BLOOD; COST OF ILLNESS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEX RATIO;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE DISTRIBUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST OF ILLNESS; DIABETES MELLITUS; GUIDELINES AS TOPIC; HUMANS; HYPERLIPIDEMIAS; NEW SOUTH WALES; OBESITY; PREVALENCE; QUALITY OF LIFE; RISK FACTORS; SEX DISTRIBUTION;

EID: 84871708431     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0124-x     Document Type: Article

References (73)

1. United Nations. UNAIDS Report on the global AIDS epidemic. 2010.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35:S64-71.
3. Diabetes Atlas fecNUc-c, David Whiting (co-chair), Leonor Guariguata, Anselm Hennis, Abdullatif Husseini, Linong Ji, Katarzyna Kissimova-Skarbek, Ingrid Libman, Elizabeth Mayer- Davis, Ayesha Motala, Venkat Narayan, Ambady Ramachandran, Gojka Roglic, Jonathan Shaw, Nick Wareham, Ping Zhang. IDF Diabetes Atlas (5th Edition). 2011.
4. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114-21. (Pubitemid 40425975)
5. Kilby JM, Tabereaux P. Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:46-50.
6. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. 1997; 127:947.
7. Eastone JA, Decker C. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med. 1997;127:948. (Pubitemid 27490630)
8. Dubé MP, Johnson D, Currier JS, Leedom JM. Protease- inhibitorassociated hyperglycaemia. Lancet. 1997;350:713-4.
9. Carr A, Samaras K, Burton S, Freund J, Chisholm D, Cooper D. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS. 1998;12:F51-8. (Pubitemid 28190689)
10. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper D. Natural history, diagnosis and prediction of HIV protease inhibitor-induced lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet. 1999;353:2094-9.
11. Hadigan C, Meigs J, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-9. (Pubitemid 32150958)
12. Calza L, Masetti G, Piergentili B, et al. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS. 2011;22:43-5.
13. Brown T, Cole S, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2000;165:1179-84. (Pubitemid 40720744)
14. De Wit S, Sabin C, Weber R, Worm SW, Reiss P, Cazanave C, El- Sadr W, Monforte A, Fontas E, Law MG, Friis-Møller N, Phillips A, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Incidence and risk factors for new-onset diabetes in HIVinfected patients: The Data Collection on Adverse Events of Anti- HIV Drugs (D:A:D) study. Diabetes Care. 2008;31:1224-9.
15. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011;53:1130-9. This important paper reports the associations of diseases of aging in treated HIV in a long established and large cohort. The incidence of CVD, diabetes, osteoporosis, and other diseases associated with aging are reported, and related to drug exposures.
16. Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012;26:303-14. While a smaller cohort than other observational studies, this study examined diabetes incidence in relation to traditional and HIV-specific risk factors.
17. Polsky S, Floris-Moore M, Schoenbaum EE, Klein RS, Arnsten JH, Howard AA. Incident hyperglycaemia among older adults with or at-risk for HIV infection. Antivir Ther. 2011;16:181-8.
18. Howard AA, Floris-Moore M, Arnsten JH, Santoro N, Fleischer N, Lo Y, Schoenbaum EE. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis. 2005;40:1492-9. (Pubitemid 40628638)
19. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, Weber K, Piessens E, Robison E, Anastos K. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32: 298-302. (Pubitemid 36331702)
20. Tien PC, Schneider M, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M, Justman JE. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007;21:1739-45. (Pubitemid 47237561)
21. Yoon C, Gulick R, Hoover DR, Vaamonde CM, Glesby MJ. Case- control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;37:1464-9. (Pubitemid 39602336)
22. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007;30:113-9. (Pubitemid 46052508)
23. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S, INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21:2445-53. (Pubitemid 350145176)
24. Milner KL, Van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology. 2010;138: 932-41
25. Mehta SH, Moore R, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr. 2003;33:577-84. (Pubitemid 36975845)
26. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007;21(16):2183-90. (Pubitemid 350287216)
27. Lee GA, Lo JC, Aweeka F, et al. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006;43(5):658-60. (Pubitemid 44267131)
28. Taylor SA, Lee GA, Pao VY, et al. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr. 2010;55(3):361-4.
29. Pao VY, Lee GA, Taylor S, et al. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers. AIDS. 2010;24(2):265-70.
30. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case control study. Lancet. 2003;361:726-35.
31. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-16. (Pubitemid 30459502)
32. van der Valk M, Gisolf E, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA. Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847-55. (Pubitemid 32424388)
33. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J American Med Assoc. 2004;292:191-201. (Pubitemid 38917996)
34. Falutz J. Management of fat accumulation in patients with HIV infection. Curr HIV/AIDS Rep. 2011;8:200-8.
35. Martínez E. Disorders of fat partitioning in treated HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25:415-27.
36. Paik IJ, Kotler D. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25:469-78.
37. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;50:499-505.
38. Levitt NS, Bradshaw D. The impact of HIV/AIDS on Type 2 diabetes prevalence and diabetes healthcare needs in South Africa: projections for 2010. Diabet Med. 2006;23:103-4.
39. Julius H, Basu D, Ricci E, Wing J, Basu JK, Pocaterra D, Bonfanti P. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital. Curr HIV Res. 2011;9:247-52.
40. Hall V, Thomsen R, Henriksen O, Lohse N. Diabetes in Sub Saharan Africa 1999-2011: epidemiology and public health implications. A systematic review. BMC Publ Health. 2011;11:564.
41. Gupta S, Shenoy V, Bairy I, Srinivasa H, Mukhopadhyay C. Diabetes mellitus and HIV as co-morbidities in tuberculosis patients of rural south India. J Infect Public Health. 2011;4:140-4.
42. Dubé MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab. 2011;25:429-42.
43. Kotler DP, Ionescu G, Johnson JA, Inada Y, He Q, Engelson ES. Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis. 2003;37 Suppl 2: S47-51. (Pubitemid 37102724)
44. Samaras K, Gan S, Peake PW, Carr A, Campbell LV. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity. 2009;17:53-9. (Pubitemid 50331903)
45. Kim PS, Woods C, Dutcher L, Georgoff P, Rosenberg A, Mican JA, Kopp JB, Smith MA, Hadigan C. Increased prevalence of albuminuria in HIV-infected adults with diabetes. PLoS One 2011;Sep 13 (Epub).
46. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIVRelated Factors. Am J Kidney Dis 2011;Dec 27 (Epub).
47. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923-9.
48. Glover SJ, Burgess P, Cohen DB, Harding SP, Hofland HW, Zijlstra EE, Allain TJ. Prevalence of diabetic retinopathy, cataract and visual impairment in patients with diabetes in sub-Saharan Africa. Br J Ophthalmol. 2012;96:156-61.
49. Reijmer YD, van den Berg E, de Bresser J, Kessels RP, Kappelle LJ, Algra A, Biessels GJ; Utrecht Diabetic Encephalopathy Study Group. Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors. Diabetes Metab Res Rev 2011;27:195-202
50. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, Rosario D, Alexander TJ, Marra C, Ances BM, Grant I; CHARTER Group. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012;78:485-92. A further study that documents less frequent achievement of the appropriate standards of care in HIV infection with diabetes.
51. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation. 2009;119:805-11.
52. Association AD. Standards of Medical Care in Diabetes - 2012. Diabetes Care. 2012;35:S11-63.
53. Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, Neumann A, Brockmeyer NH, Gelbrich G, Erbel R, Neumann T, On behalf of the German Competence Network Heart Failure and the German Competence Network for HIV/AIDS. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiolog. 2012;19:267-74
54. Backus LI, Boothroyd D, Philips B, Belperio P, Halloran J, Mole L. Assessment of the quality of diabetes care for HIV-infected patients in a national health care system. AIDS Patient Care STDS. 2011;25:203-6.
55. Satlin MJ, Hoover D, Glesby MJ. Glycemic control in HIVinfected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS. 2011;25:5-12.
56. Kalra S, Unnikrishnan A, Raza SA, Bantwal G, Baruah MP, Latt TS, Shrestha D, John M, Katulanda P, Somasundaram N, Sahay R, Pathan F. South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocrinol Metab. 2011;14:242-50.
57. Petoumenos K, Worm S. HIV infection, aging and cardiovascular disease: epidemiology and prevention. Sex Health. 2011;8:465-73.
58. Janiszewski PM, Ross R, Despres JP, Lemieux I, Orlando G, Carli F, Bagni P, Menozzi M, Zona S, Guaraldi G. Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study. PLoS One 2011;6:Sept 22 (Epub).
59. Bucher H, Richter W, Glass T, et al. Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2011;Dec 9 (Epub).
60. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC, Swiss HIV, Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7:404-10. (Pubitemid 44123252)
61. Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD, D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7:218-30.
62. The Data Collection on Adverse Events of Anti-HIV Drugs (D: A:D) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003. An important paper documenting health benefits in cardiovascular event reduction after smoking cessation in HIV-infected participants.
63. The DAD Study Group. Class of antiretrovirals and risk of myocardial infarction. N Engl J Med 2007;356:1723-35
64. Triant VA, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, Miller V, Strobos J. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin Infect Dis. 2012;54:408-13.
65. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-7. The first study showing that dietary intervention at initiation of HAART can prevent development of lipid disturbances.
66. Petoumenos K,Worm S, Reiss P, deWit S, d'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M, D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med. 2011;12:412-21.
67. Worm SW, Sabin C,Weber R, Reiss P, El-SadrW, Dabis F, DeWit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIVinfection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti- HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-30.
68. Ribaudo H, Benson C, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52:929-40.
69. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993-2004.
70. Worm SW, Kamara D, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Mller N, Mercie P, Lundgren JD, Sabin C. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25:1497-504.
71. Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. J Am Coll Cardiol. 2012;59:979-88.
72. Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG, DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491-501.
73. Curtis J, Newall HD, Samaras K. The heart of the matter: Cardiometabolic care in youth with psychosis. Early Interven Psychosis 2012.